Merck & Co., Inc. (MRK) vs Taiwan Semiconductor Manufacturing Company Limited (TSM)

Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.

Taiwan Semiconductor Manufacturing Co. (TSMC) is the world’s largest pure-play semiconductor foundry, holding roughly 70% market share in 2025. Founded in 1987 as a joint venture between Philips, the Taiwan government, and private investors, the company listed in Taiwan in 1994 and later launched its US ADR in 1997. TSMC’s vast scale and advanced manufacturing capabilities support strong operating margins, even within the highly competitive foundry industry. The ongoing shift toward the fabless semiconductor model has also provided meaningful growth tailwinds. Its distinguished customer base includes Apple, AMD, and Nvidia, which rely on TSMC’s leading-edge process technologies for their chip designs. The company employs more than 83,000 people.